Discovery Labs to Develop $500-Million Innovation Hub at Former GSK Site
The Discovery Labs, a platform company that develops co-working laboratory and office space for healthcare, life sciences and technology-enabled companies, has announced it is redeveloping a pair of sites in Pennsylvania, the former GlaxoSmithKline’s (GSK) one-million-square foot Upper Merion West campus and the 640,000-square-foot Innovation at Renaissance Campus in King of Prussia, into a coworking community for healthcare, life sciences and technology companies.
The Discover Labs says the size of each facility enables enterprise-level companies to work side by side with startup and emerging companies. At the center of the community is IQ Connect, The Discover Labs incubator, a 100,000-square-foot business incubator and laboratory, formed in partnership with The Pennsylvania Biotechnology Center. IQ Connect is designed to bring together researchers, entrepreneurs and product-development startups, along with human resources, venture capital, investment banking and other business services to pursue discovery and development of scientific, life sciences, tech-enabled industrial, venture and consumer products.
The Discovery Labs’ design for the new site includes large, 85-foot central atriums, 16-foot ceilings, 20-foot-tall penthouse spaces and glass walkways that connect 12 buildings ranging from 50,000 to 125,000 square feet. Outdoor spaces and indoor/outdoor atriums will be provided for workers to access fresh air. Open spaces will be made available featuring coffee shops, a $10-million conference center, video conferencing, a 275-seat auditorium and adjoining, meeting and education rooms. The design also includes a 14,000-square-foot fitness center, as well as outdoor recreational options, an amphitheater, restaurants and shuttle transportation to train lines.
The first Discovery Labs in King of Prussia is the prototype for a global rollout of The Discovery Labs.
Tenants include Children’s Hospital of Philadelphia, Thomas Jefferson University, GlaxoSmithKline, Tosoh Biosciences, Crown Castle and MedRisk.
Source: Discovery Labs